baber/WOPTO huggingface dataset:
Patent MD-20060114-A (MD)
Inventor: COVALIOV VICTOR
IPC: C02F1/465
Filed: 2006-04-10
Abstract: Inventia se refera la tehnica de separare a sistemelor coloidale stabile, de extragere a particulelor tari suspendate in lichide si de imbogatire a substantelor utile, cu utilizarea gazelor electrolizate si poate fi aplicata in tehnologiile de epurare a apelor reziduale, pentru regenerarea si epurarea apelor tehnologice prelucrate in diverse ramuri ale industriei, in special pentru separarea suspensiilor stabile in vinificatie, care  contin produse organice – drojdii, proteine, floculanti si alte substante, produse de origine minerala – particule de bentonita, albastru de Berlin, formate in urma demetalizarii materiei prime vinicole si alte componente. Esenta inventiei consta in aceea ca electroflotatorul pentru separarea suspensiei contine carcasa cu conducte de admisiune si evacuare a lichidului de prelucrat si a precipitatului, colector de spuma, anod si catod cu bucse electroconductoare. Electroflotatorul contine suplimentar un decantor cu sicane inclinate si cu o  zona de colectare si evacuare a precipitatului, iar colectorul de spuma este dotat cu o incarcatura feromagnetica sferica, situata pe o plasa de separare, amplasatain canalul colectorului de spuma, un solenoid, amplasat  intr-o carcasa ermetica, conectat printr-un reostat la o sursa de curent alternativ. Pe conducta de aer a colectorului de spuma este instalatao conducta de suflare a aerului cu ventilator-suflor de spuma pentru aspirare a gazelor si suflareadirectionata a spumei. Anodul de grafit este confectionat perforat pentru introducerea prin el a suspensiei de prelucrat, iar catodul - de tip perie-sarma din otel inoxidabil pentru a  face posibila electroflotarea cu bule mici.
Patent NZ-202292-A (NZ)
Title: 5-hydroxy-2-benzothiazolesulfonamide and treatment of intraocular pressure
Inventor: WOLTERSDORF O W
IPC: C07D277/80
Filed: 1982-10-26
Abstract: Hydroxy substituted-2-benzothiazolesulfonamide is useful for the tropical treatment of elevated intraocular pressure. Ophthalmic compositions including drops and inserts are disclosed.
Patent NZ-208831-A (NZ)
Title: Imidazolium derivatives and pharmaceutical compositions
Inventor: DIAMOND J
IPC: C07D233/61
Filed: 1984-07-09
Abstract: The imidazolium salts described are useful as antiarrhythmic agents. A method of treating arrhythmia by increasing the refractoriness of cardiac tissue is provided as well as pharmaceutical formulations containing such imidazolium salts.
Patent NZ-214354-A (NZ)
Title: Sliding door controller:arrested door motion causes cessation or reversal of door movement according to door position
Inventor: MCCLOSKY P S
IPC: G05D3/20
Filed: 1985-11-28
Abstract: PCT No. PCT/AU85/00296 Sec. 371 Date Jul. 30, 1986 Sec. 102(e) Date Jul. 30, 1986 PCT Filed Nov. 29, 1985 PCT Pub. No. WO86/03249 PCT Pub. Date Jun. 5, 1986.A controller for controlling the movement of a member such as a sliding door driven by a motor. The door is controlled by the use of a motion detector coupled with the door. Pulses from the motion detector are counted by control circuitry, and the door is moved at a reduced speed in the region of its limits of travel. The limits are defined by the number of pulses from the motion detector equalling a predetermined value. The motor is de-energized if a stationary state of the door is detected in the low speed region, and reversed if a stationary condition is detected in the remainder of its movement.
Patent NZ-226954-A (NZ)
Title: Power tool with compact i.c. engined power head
Inventor: TUGGLE LLOYD H
IPC: F02B63/02
Filed: 1988-11-14
Abstract: A gasoline engine driven flexible line trimmer is provided with a modularly constructed power head section which significantly facilitates the original manufacturing assembly, and subsequent service disassembly, of the power head. In a clutch drive embodiment thereof, the power head has four readily separable modules - an engine module comprising a main engine shroud to which the engine is internally secured; a fan housing module; a starter module comprising a starter housing and a recoil starter mechanism retained therein; and a coupling module comprising a clutch housing carrying therein structure for operatively interconnecting the engine's clutch to the flexible drive shaft disposed within the trimmer shaft. In a direct drive version thereof, the power head has two separable modules - the engine module and a combined fan housing, starter and coupling module defined by a single housing within which the starter and coupling structure is carried. The main shroud is provided with a specially designed wall section which supports the engine, defines a closure wall of its crankcase, forms an air-fuel mixture passage for a carburetor externally supported on the wall section and supports a reed valve within the crankcase. The shroud defines an external protective recess in which the carburetor is positioned and, in one embodiment, defines a portion of the engine's fuel tank. Pull rope installation in the starter mechanism is facilitated and made safer by pulley locking and retaining structure incorporated in the starter module, and improved air filter element sealing is provided by virtue of a specially designed air filter housing and choke plate assembly associated with the carburetor. Shaft vibration transmitted to the trimmer user through the supporting shoulder strap structure is significantly reduced by a specially designed resilient strap connector assembly securable to the trimmer shaft.
Patent NZ-227041-A (NZ)
Title: Method of making coloured hydrophilic contact lenses
Inventor: NORDUCY KENNETH W
IPC: C08J7/043
Filed: 1988-11-22
Abstract: There is disclosed a method for making colored hydrophilic contact lenses. A contact lens constructed of hydrophilic polymer that is substantially devoid of the functional groups -COOH, -OH, -NH-R, wherein R is hydrogen or C1 to C8 alkyl, -NCO and epoxy is provided. At least a portion of the surface of the lens is coated with a color coat comprising at least one pigment, binding polymer having functional groups selected from at least one of -COOH, -OH, and -NH-R, wherein R is hydrogen or C1 to C8 alkyl, and an additional compound having at least two groups per molecule of -NCO. The coated lens is subjected to conditions which cause the color coat to adhere to the lens.
Patent NZ-227299-A (NZ)
Title: Hydroxy- or keto-amine derivatives and pharmaceutical compositions
Inventor: GAWELL LARS IVAR
IPC: C07C215/28
Filed: 1988-12-13
Abstract: Compounds with the general formula I <CHEM> wherein n is 0 or 1, Z is CO or CH(OH), R<1> and R<2> are equal or different and, when equal, hydrogen, methyl, ethyl or propyl and, when different, R<1> is hydrogen and R<2> is methyl, ethyl, propyl or isopropyl, X and Y represent hydrogen, halogen, CF3, CN or an alkyl group, straight or branched having 1-3 carbon atoms, in the ortho, meta or para position provided that when X is in the ortho position and other than hydrogen then Y is other than hydrogen, and when Y is in the ortho position and other than hydrogen then X is other than hydrogen, R represents a straight or branched saturated or unsaturated 1-6 carbon alkyl group, a 3-6 carbon cycloalkyl group, a phenyl group, which may be unsubstituted or may carry a ring substituent X<1>, X<1> preferably being a halogen, or R represents hydrogen, in racemic or optically active form and when Z is CH(OH) also mixtures of diastereomers or a pure diastereomer, with the proviso that the racemate of the compound wherein R<1> and R<2> is hydrogen, X is p-Cl, Y is hydrogen, Z is CO, n is 0 and R is methyl is excluded, or pharmaceutically acceptable salts thereof, processes for the production of said compounds and the use of the said compounds for the treatment of mental disturbances.
Patent NZ-229961-A (NZ)
Title: Use of 4-(n-heterocyclyl)-6-((hetero)aromaticsulphonyl)benzo(b)pyran derivatives for preparing medicaments for lung or urinary system disorders
Inventor: ENGLERT HEINRICH CHRISTIAN
IPC: A61K31/425
Filed: 1989-07-17
Abstract: The use of 3,4-dihydro-2H-benzo[b]pyrans of the formula I <IMAGE>  in which   R<1> is H, OH, (C1-C2)-alkoxy, (C1-C2)-alkyl or NR<4>R<5>, where R<4> and R<5> are identical or different and are H, (C1-C2)-alkyl or (C1-C3)-alkylcarbonyl, R<2> and R<3> are identical or different and are alkyl with 1-4 C atoms, Ar is an aromatic or heteroaromatic system which is unsubstituted or substituted by 1 to 3 identical or different radicals (C1-C2)-alkyl, (C1-C2)-alkoxy, halogen, trifluoromethyl, CN, NO2, CO-(C1-C2)-alkyl or SOm-(C1-C2)-alkyl with m = 1 or 2,   n is 1 or 2, X is a chain (CH2)r which can be interrupted by a heteroatom O, S or NR<6> where R<6> is H or (C1-C4)-alkyl and r is the numbers 2, 3, 4 or 5, for the production of a medicament for urinary tract disorders.
Patent NZ-237589-A (NZ)
Title: Recovering fetal cells from maternal blood using antibodies for cell surface antigens
Inventor: SIMONS MALCOLM J
IPC: C12N5/073
Filed: 1991-03-26
Abstract: PCT No. PCT/AU91/00115 Sec. 371 Date Nov. 2, 1992 Sec. 102(e) Date Nov. 2, 1992 PCT Filed Mar. 27, 1991 PCT Pub. No. WO91/14768 PCT Pub. Date Oct. 3, 1991.The present invention provides a method for selectively recovering fetal cells from a maternal blood sample. The method is performed on a blood sample from a pregnant woman having different first and second cell surface antigens expressed by a first allele of a polymorphic genetic locus and a second allele of a polymorphic genetic locus. The method separates maternal and fetal cells based on differential reactivities of the cells to antibodies specific for polymorphic cell surface antigens, particularly the HLA antigens. In particular, the fetal and maternal cells are separated based on the non-reactivity of the fetal cells to an antibody specific for a cell surface antigen encoded by a non-transmitted maternal allele. The method can be performed using solid phase-affixed antibody and recovering non-bound cells or using fluorescent labeled antibody and recovering unlabeled cells by fluorescence-activated cell sorting. In a preferred embodiment, the cells are also contacted with a second antibody specific for the second cell surface antigen. Fetal cells are separated based on their reaction with, at most, one of the antibodies.
Patent NZ-246629-A (NZ)
Title: Saline soluble fibres for refractory insulation comprising greater than 58 percent by weight of silicon dioxide
Inventor: JUBB GARY ANTHONY
IPC: D06L1/00
Filed: 1993-01-15
Abstract: A use is disclosed comprising the repeated exposure to temperatures of 1000 DEG C or more of refractory insulation comprising saline soluble fibres having a shrinkage as specified of less than 3.5% when exposed to 1000 DEG C for 24 hours and having a shrinkage as specified of less than 3.5% when exposed to 800 DEG C for 24 hours, the saline soluble fibres comprising vitreous fibres comprising SiO2 and either one or both of CaO or MgO and having a composition comprising (in weight %):- <TABLE> and being essentially free of fluxing components such as alkali metal oxides and boron oxide. <IMAGE>
Patent NZ-248054-A (NZ)
Title: Wound healing, gastrointestinal injury, disease or ulcer treatment using milk extract containing cell growth stimulating factors
Inventor: BALLARD FRANCIS JOHN
IPC: C12N5/071
Filed: 1993-07-02
Abstract: A milk product extract composition comprising a plurality of cell growth stimulating factors in a concentrated form for use as a medicament fir healing surface wounds, gastrointestinal injuries, diseases or ulcers.  The growth stimulating factors have isoelectric points between 6.0 and 10.5.  The milk product extract includes 0.5 w/w casein, alpha lactalbumin, beta lactoglobulin, immuno globulin or albumin or a cheese whey extract, based on the total weight of the composition.
Patent NZ-284412-A (NZ)
Title: Apolipoprotein E polymorphism and treatment of Alzheimer's Disease
Inventor: POIRIER JUDES
IPC: C12Q1/68
Filed: 1995-04-26
Abstract: he present invention relates to a method for the identification of human subjects (including Alzheimer disease) to be responsive to cholinomimetic therapy, comprises determining the presence of apoE2 and E3 alleles (and the absence of apoE4) in a biological sample of the patient directly using appropriate apoE2 and E3 probes or indirectly by phenotyping, and wherein one or two copies of apoE2 or E3 gene allele indicates a predisposition to respond to cholinomimetics-based therapies.  Divisional filed as 500375
Patent NZ-313185-A (NZ)
Title: 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
Inventor: PEVARELLO PAOLO
IPC: C07C231/12
Filed: 1996-07-05
Abstract: 2-(4-substituted)-benzylamino-2-methyl-propanamides compounds, having CNS activity, of general formula (I) wherein: n is zero, 1, 2 or 3; X is -O-, -S-, -CH2- or -NH-; each of R and R1 independently is hydrogen, C1-C6 alkyl, halogen, hydroxy, C1-C4 alkoxy or trifluoromethyl; each of R2, R3 and R4 independently is hydrogen, C1-C6 alkyl or C3-C7 cycloalkyl; and the pharmaceutically acceptable salts thereof, are disclosed.
Patent NZ-338095-A (NZ)
Title: Membrane clamp for a waste fitting having three components
Inventor: CHADWICK BRAD RONALD
IPC: E03C1/12
Filed: 1999-09-29
Abstract: membrane clamp 10 when used with a waste outlet fitting of the type herein before described is claimed.  The waste outlet fitting comprises three or four components, namely an inlet unit having a bitruncated spherical section 21, a grate 20 supportable by the inlet unit, a basal unit 23 having a sleeve for connecting to a waste pipe and including a flange and a connecting portion and optionally an intermediate unit 22 located between the inlet and basal unit 23.  The inlet unit is pivotal on its bitruncate spherical section 21 with respect to basal unit 23 or when intermediate unit 22 is present.  Clamp 10 is in the form of a plug having a waste passageway extending from one side of the plug to the other.  The plug is designed to engage with basal unit 23 of the waste outlet fitting of the type herebefore described in such a manner as to sealingly retain an adjacent membrane between the plug and basal unit 23.
Patent NZ-502039-A (NZ)
Title: Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
Inventor: SUMEGI BALAZS
IPC: A61K33/243
Filed: 1998-06-22
Abstract: Pharmaceutical compositions, which have enhanced antitumour activity or reduced side effects, are described.  They comprise a known active substance, which has an antitumour effect, or a pharmaceutically acceptable salt thereof, and a hydroximic acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.
Patent NZ-502689-A (NZ)
Title: Billing method applied to a mobile packet communication network
Inventor: KOBAYASHI SHINJI
IPC: H04N1/00
Filed: 1999-08-27
Abstract: When an IP (Information Provider) server is accessed from a mobile station, a gateway server determines whether or not the IP server is to be IP billed (S101). If it is not to be IP billed, then user billing is applied. In this case, the gateway server sends a user management number of the mobile station and the number of exchanged data packets to a billing system (S102). The billing system calculates a communication fee in accordance with the number of packets, and issues a bill to the user specified by the user management number (S103). On the other hand, if the accessed IP server is to be billed, IP billing is applied instead. In this case, the gateway server sends the number of exchanged packets and the address of the accessed IP server to the billing system (S104). The billing system then calculates and issues an IP bill according to the number of exchanged packets (S105).
Patent NZ-506618-A (NZ)
Title: Dietary composition comprising gamma linolenic acid a desaturase inhibitor and an arachidonic acid metabolism inhibitor for diminishing symptoms of inflammatory disorders
Inventor: CHILTON FLOYD H
IPC: A23L1/30
Filed: 1999-02-12
Abstract: Described are dietary strategies that will produce natural antagonists of arachidonic acid (AA) in inflammatory cells, thereby reducing the synthesis of pro-inflammatory eicosanoids, but without increasing serum levels of AA.  Dietary supplements comprising gammalinoleic acid (GLA) are beneficial in treating inflammatory disease through an increase in neutrophil GLA, but there is a concomitant increase in serum AA.  It has been discovered that neutrophils, the inflammatory response cells, do not possess a -5 desaturase.  Thus, the product of GLA elongation, dihomogammalinoleic acid (DGLA) cannot be converted to AA and eicosanoids.  However, in serum, DGLA formed from the elongation of GLA is converted to AA via the action of a -5 desaturase.  This build-up of serum AA is likely to have harmful consequences in humans.  For example, previous studies have demonstrated that increases in AA of this magnitude can increase platelet reactivity. Increases in sensitivity of platelets to stimuli in most cases are not desirable.  Providing a -5 desaturase inhibitor has circumvented this problem, in this case, eicosapentaenoic acid (EPA) in combination with the GLA, which prevents the serum increase in AA levels upon GLA administration. Thus, there are provided herein dietary fatty acid regimens that may be used to inhibit the increase of serum arachidonic acid when GLA is provided as a dietary supplement and thereby control inflammation.
Patent NZ-507485-A (NZ)
Title: Method for removing bone matrix where the bone is partly inside a chamber whereupon a higher pressure is provided within the chamber
Inventor: SCARBOROUGH NELSON L
IPC: A61L27/00
Filed: 1998-03-11
Abstract: A method for treating, e.g. cleaning, the interior of a fluid permeable workpiece by establishing a flow of fluid suing pressure differentials. More especially, the method provides for treating the interior matrix of bone that is intended for implantation using an apparatus described which comprises: (a) providing a fluid pressure chamber; (b) positioning at least a first portion of a bone within the interior of the fluid pressure chamber and at least a second portion of the bone outside the fluid pressure chamber; and (c) supplying a fluid at a pressure greater than atmospheric pressure to the fluid pressure chamber to force the fluid to flow from within the chamber through the interior matrix of the bone to a location outside the fluid pressure chamber. The method further comprised of one or more treatment liquids to variously clean, de-fat, sterilise, virally inactivate, disinfect, and/or de-mineralise the bone to facilitate the visualisation of its structure or to impregnate the bone with one or more pharmacological agents (antibiotics, bone growth factors, etc) so that the bone could act as a drug delivery system.
Patent NZ-507621-A (NZ)
Title: HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy
Inventor: ALBRECHT JANICE K
IPC: A61K31/70
Filed: 2000-10-18
Abstract: Use of ribavirin and interferon alpha to prepare pharmaceutical compositions for treating antiviral treatment naive patient having chronic hepatitis C infection.  The treatment is a combination therapy designed to eradicate detectable HCV-RNA.  It involves using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a period of from 20 up to 50 weeks.
Patent NZ-507885-A (NZ)
Title: 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine (descarbonylethoxyloratadine) pharmaceutical compositions; useful for treating allergic reactions
Inventor: KOU JIM H
IPC: A61P11/02
Filed: 1999-07-08
Abstract: A pharmaceutical composition comprises an anti-allergic effective amount of descarbonylethoxyloratadine (DCL) in a pharmaceutically acceptable carrier medium comprising a DCL-protective amount of a pharmaceutically acceptable basic salt and optionally at least one pharmaceutically acceptable disintegrant, wherein the pharmaceutically acceptable carrier medium is substantially free (has < 1%) of acidic excipients. The preferred basic salt is calcium dibasic phosphate and the preferred disintegrants are microcrystalline cellulose and starch sufficient to provide dissolution of at least 80% by weight of a pharmaceutical composition in 45 minutes. Preferably the pharmaceutical composition contains less than 1% by weight of N-formylDCL after storage at 25oC and 60% relative humidity for at least 24 months. Also described is a pharmaceutical composition, which comprises 5 mg of DCL in a pharmaceutically acceptable carrier medium, wherein the pharmaceutically acceptable carrier medium is substantially free (has < 1%) of acidic excipients. The compositions thereof are useful for treating allergic reactions.
Patent NZ-508878-A (NZ)
Title: IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
Inventor: WOOD WILLIAM I
IPC: A61K/
Filed: 1999-05-14
Abstract: A polypeptide has at least 80% amino acid sequence identity with PRO1031 whose sequence is shown in SEQ ID NO:1 or PRO1122 whose sequence is shown in SEQ ID NO:3. The nucleic acid sequence is the sequence in SEQ ID NO:2 and 4 respectively. Also described is an antibody that specifically binds to the polypeptide, a vector comprising that will encode the polypeptide and an ex-vivo host cell comprising the vector. The polypeptide can be used in a medicament for treating a degenerative cartilaginous disorder.
Patent NZ-512526-A (NZ)
Title: 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
Inventor: BOLLI MARTIN
IPC: C07D401/04
Filed: 2000-08-16
Abstract: The present invention relates to novel bis-sulfonamides represented, for example, by formula I below and a pure diastereomer, a mixture of diastereomers, a diastereomeric racemate, a mixture of diastereomeric racemates and meso-forms and a pharmaceutically acceptable salt thereof, wherein R1 -R4 and R6 are as described in the specification. The present invention also relates to a process for manufacturing those compounds, pharmaceutical compositions containing one or more of those compounds as endothelin antagonists, which are useful in treating a subject having a disorder involving endothelin.
Patent NZ-512991-A (NZ)
Title: Catamaran with M-shaped side by side double boat hull to suppress wave formation
Inventor: ROBINSON CHARLES W
IPC: B63B1/12
Filed: 2001-07-17
Abstract: The present invention relates to a "side by side" double hull arrangement of a watercraft with each hull (as disclosed in NZ patent application 510758, WO 00/17041) having a wave suppressing "M-shaped" hull design. Each hull comprises a central displacement body flanked by two downwardly extending outer skirts. The outer skirts are attached to the displacement body by planing wings having wing channels. The bow wave is directed into the wing channels, thereby increasing planing efficiency and reducing the effect of such waves on other boats and the shoreline. Addition to 510758
Patent NZ-517987-A (NZ)
Title: Preparation of polyisobutylenephenol containing mannich adducts useful as detergents in fuel compositions
Inventor: LANGE ARNO
IPC: C08F8/32
Filed: 2000-10-05
Abstract: A method for producing Mannich adducts that contain polyisobutylene phenol is disclosed wherein the method comprises: a) alkylating a phenol with highly-reactive polyisobutylene having a numerical average molecular weight of less than 1000 and with a polydispersivity of less than 3.0, at a temperature lower than 50 °C and in the presence of an alkylation catalyst; b) reacting the reaction product from a) with; b1) an aldehyde, selected among formaldehydes, an oligomer and a polymer of formaldehyde, and with; b2) at least one amine which has at least one primary or one secondary amino function. Mannich adducts that can be obtained by using this method, and that can be used as detergent additives in fuel compositions and lubricant compositions, and additive concentrates, fuel compositions and lubricant compositions containing these Mannich adducts are also disclosed.